2016
DOI: 10.1016/j.canrad.2016.03.006
|View full text |Cite
|
Sign up to set email alerts
|

Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
10
1

Year Published

2016
2016
2019
2019

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 14 publications
(11 citation statements)
references
References 29 publications
0
10
1
Order By: Relevance
“…Patterns of tumor recurrence have been well studied in the last decade 13 , 14 , 21 23 . Most studies evaluated four recurrence types according to the classification of Pope et al .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Patterns of tumor recurrence have been well studied in the last decade 13 , 14 , 21 23 . Most studies evaluated four recurrence types according to the classification of Pope et al .…”
Section: Discussionmentioning
confidence: 99%
“…: local, distant, diffuse, multifocal 23 . The predominant type is local tumor recurrence 13 , 21 , 23 25 . Whereas local tumor recurrence is associated with a better prognosis, the remaining recurrence patterns are associated with impaired overall survival 15 .…”
Section: Discussionmentioning
confidence: 99%
“…In 1997, Glass et al 20 tested this combined approach of stereotactic radiotherapy and chemotherapy with cisplatin. Since then, several studies that combined HFSRT with various drugs (paclitaxel, TMZ, topotecan, gefitinib, sunitinib, fotemustine, panobinostat, or bevacizumab) 20 , 23 , 27 , 28 , 30 , 33 , 35 - 38 , 40 , 41 , 43 - 46 have been conducted. According to these studies, combined modality management appears to be feasible and well tolerated, and the results are encouraging especially with bevacizumab.…”
Section: Discussionmentioning
confidence: 99%
“…According to these studies, combined modality management appears to be feasible and well tolerated, and the results are encouraging especially with bevacizumab. 33 , 37 , 43 , 45 , 46 The RTOG 1205 randomized phase II trial could shed new light on the efficacy of this strategy and clarify the role of bevacizumab in the management of HGG recurrence.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation